3rd Quarter - Report

THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Health Issues HCR

S. 2333, Pandemic and All-Hazards Preparedness and Response Act. H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.

LobbyistCovered position, as disclosed
GREG D'ANGELO New White House Office of Management and Budget, Associate Director of Health Programs; Senate Committee on the Budget (Sen. Gregg, Sen. Sessions, and Sen. Enzi), Professional Staff Member
DONALD KENT —
MARY BETH SAVARY TAYLOR New Joint Economic Committee, General Counsel; U.S. Senator Connie Mack, Legislative Assistant

Contacted: SENATE

Bills named: H.R. 4421 (118th), S. 2333 (118th)

Aerospace AER

FAA reauthorization - increasing access to naloxone.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Aviation/Airlines/Airports AVI

Increasing access to Naloxone.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.